Pregabalin Pfizer

Țară: Uniunea Europeană

Limbă: engleză

Sursă: EMA (European Medicines Agency)

Cumpara asta acum

Prospect Prospect (PIL)
12-01-2024

Ingredient activ:

pregabalin

Disponibil de la:

Upjohn EESV

Codul ATC:

N03AX16

INN (nume internaţional):

pregabalin

Grupul Terapeutică:

Antiepileptics,

Zonă Terapeutică:

Anxiety Disorders; Epilepsy

Indicații terapeutice:

Neuropathic painPregabalin Pfizer is indicated for the treatment of peripheral and central neuropathic pain in adults.EpilepsyPregabalin Pfizer is indicated as adjunctive therapy in adults with partial seizures with or without secondary generalisation.Generalised Anxiety DisorderPregabalin Pfizer is indicated for the treatment of Generalised Anxiety Disorder (GAD) in adults.

Rezumat produs:

Revision: 29

Statutul autorizaţiei:

Authorised

Data de autorizare:

2014-04-10

Prospect

                                56
B. PACKAGE LEAFLET
57
PACKAGE LEAFLET: INFORMATION FOR THE USER
PREGABALIN PFIZER 25 MG HARD CAPSULES,
PREGABALIN PFIZER 50 MG HARD CAPSULES,
PREGABALIN PFIZER 75 MG HARD CAPSULES,
PREGABALIN PFIZER 100 MG HARD CAPSULES,
PREGABALIN PFIZER 150 MG HARD CAPSULES,
PREGABALIN PFIZER 200 MG HARD CAPSULES,
PREGABALIN PFIZER 225 MG HARD CAPSULES,
PREGABALIN PFIZER 300 MG HARD CAPSULES
pregabalin
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS
MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU
.
-
Keep this leaflet. You may need to read it again.
-
If you have any further questions, ask your doctor or pharmacist.
-
This medicine has been prescribed for you only. Do not pass it on to
others. It may harm them,
even if their signs of illness are the same as yours.
-
If you get any side effects, talk to your doctor or pharmacist. This
includes any possible side
effects not listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET
1.
What Pregabalin Pfizer is and what it is used for
2.
What you need to know before you take Pregabalin Pfizer
3.
How to take Pregabalin Pfizer
4.
Possible side effects
5.
How to store Pregabalin Pfizer
6.
Contents of the pack and other information
1.
WHAT PREGABALIN PFIZER IS AND WHAT IT IS USED FOR
Pregabalin Pfizer belongs to a group of medicines used to treat
epilepsy, neuropathic pain and
Generalised Anxiety Disorder (GAD) in adults.
PERIPHERAL AND CENTRAL NEUROPATHIC PAIN:
Pregabalin Pfizer is used to treat long lasting pain caused
by damage to the nerves. A variety of diseases can cause peripheral
neuropathic pain, such as diabetes
or shingles. Pain sensations may be described as hot, burning,
throbbing, shooting, stabbing, sharp,
cramping, aching, tingling, numbness, pins and needles. Peripheral and
central neuropathic pain may
also be associated with mood changes, sleep disturbance, fatigue
(tiredness), and can have an impact
on physical and social functioning and overall quality of life.
EPILEPSY:
Pregabalin Pfizer is used to treat a certain form of epilepsy
                                
                                Citiți documentul complet
                                
                            

Caracteristicilor produsului

                                1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE MEDICINAL PRODUCT
Pregabalin Pfizer 25 mg hard capsules
Pregabalin Pfizer 50 mg hard capsules
Pregabalin Pfizer 75 mg hard capsules
Pregabalin Pfizer 100 mg hard capsules
Pregabalin Pfizer 150 mg hard capsules
Pregabalin Pfizer 200 mg hard capsules
Pregabalin Pfizer 225 mg hard capsules
Pregabalin Pfizer 300 mg hard capsules
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Pregabalin Pfizer 25 mg hard capsules
Each hard capsule contains 25 mg of pregabalin.
Pregabalin Pfizer 50 mg hard capsules
Each hard capsule contains 50 mg of pregabalin.
Pregabalin Pfizer 75 mg hard capsules
Each hard capsule contains 75 mg of pregabalin.
_ _
Pregabalin Pfizer 100 mg hard capsules
Each hard capsule contains 100 mg of pregabalin.
Pregabalin Pfizer 150 mg hard capsules
Each hard capsule contains 150 mg of pregabalin.
_ _
Pregabalin Pfizer 200 mg hard capsules
Each hard capsule contains 200 mg of pregabalin.
_ _
Pregabalin Pfizer 225 mg hard capsules
Each hard capsule contains 225 mg of pregabalin.
Pregabalin Pfizer 300 mg hard capsules
Each hard capsule contains 300 mg of pregabalin.
_ _
Excipients with known effect
Pregabalin Pfizer 25 mg hard capsules
Each hard capsule also contains 35 mg lactose monohydrate.
Pregabalin Pfizer 50 mg hard capsules
Each hard capsule also contains 70 mg lactose monohydrate.
Pregabalin Pfizer 75 mg hard capsules
Each hard capsule also contains 8.25 mg lactose monohydrate.
Pregabalin Pfizer 100 mg hard capsules
Each hard capsule also contains 11 mg lactose monohydrate.
Pregabalin Pfizer 150 mg hard capsules
Each hard capsule also contains 16.50 mg lactose monohydrate.
Pregabalin Pfizer 200 mg hard capsules
Each hard capsule also contains 22 mg lactose monohydrate.
3
Pregabalin Pfizer 225 mg hard capsules
Each hard capsule also contains 24.75 mg lactose monohydrate.
Pregabalin Pfizer 300 mg hard capsules
Each hard capsule also contains 33 mg lactose monohydrate.
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Hard cap
                                
                                Citiți documentul complet
                                
                            

Documente în alte limbi

Prospect Prospect bulgară 12-01-2024
Caracteristicilor produsului Caracteristicilor produsului bulgară 12-01-2024
Raport public de evaluare Raport public de evaluare bulgară 07-05-2014
Prospect Prospect spaniolă 12-01-2024
Caracteristicilor produsului Caracteristicilor produsului spaniolă 12-01-2024
Raport public de evaluare Raport public de evaluare spaniolă 07-05-2014
Prospect Prospect cehă 12-01-2024
Caracteristicilor produsului Caracteristicilor produsului cehă 12-01-2024
Raport public de evaluare Raport public de evaluare cehă 07-05-2014
Prospect Prospect daneză 12-01-2024
Caracteristicilor produsului Caracteristicilor produsului daneză 12-01-2024
Raport public de evaluare Raport public de evaluare daneză 07-05-2014
Prospect Prospect germană 12-01-2024
Caracteristicilor produsului Caracteristicilor produsului germană 12-01-2024
Raport public de evaluare Raport public de evaluare germană 07-05-2014
Prospect Prospect estoniană 12-01-2024
Caracteristicilor produsului Caracteristicilor produsului estoniană 12-01-2024
Raport public de evaluare Raport public de evaluare estoniană 07-05-2014
Prospect Prospect greacă 12-01-2024
Caracteristicilor produsului Caracteristicilor produsului greacă 12-01-2024
Raport public de evaluare Raport public de evaluare greacă 07-05-2014
Prospect Prospect franceză 12-01-2024
Caracteristicilor produsului Caracteristicilor produsului franceză 12-01-2024
Raport public de evaluare Raport public de evaluare franceză 07-05-2014
Prospect Prospect italiană 12-01-2024
Caracteristicilor produsului Caracteristicilor produsului italiană 12-01-2024
Raport public de evaluare Raport public de evaluare italiană 07-05-2014
Prospect Prospect letonă 12-01-2024
Caracteristicilor produsului Caracteristicilor produsului letonă 12-01-2024
Raport public de evaluare Raport public de evaluare letonă 07-05-2014
Prospect Prospect lituaniană 12-01-2024
Caracteristicilor produsului Caracteristicilor produsului lituaniană 12-01-2024
Raport public de evaluare Raport public de evaluare lituaniană 07-05-2014
Prospect Prospect maghiară 12-01-2024
Caracteristicilor produsului Caracteristicilor produsului maghiară 12-01-2024
Raport public de evaluare Raport public de evaluare maghiară 07-05-2014
Prospect Prospect malteză 12-01-2024
Caracteristicilor produsului Caracteristicilor produsului malteză 12-01-2024
Raport public de evaluare Raport public de evaluare malteză 07-05-2014
Prospect Prospect olandeză 12-01-2024
Caracteristicilor produsului Caracteristicilor produsului olandeză 12-01-2024
Raport public de evaluare Raport public de evaluare olandeză 07-05-2014
Prospect Prospect poloneză 12-01-2024
Caracteristicilor produsului Caracteristicilor produsului poloneză 12-01-2024
Raport public de evaluare Raport public de evaluare poloneză 07-05-2014
Prospect Prospect portugheză 12-01-2024
Caracteristicilor produsului Caracteristicilor produsului portugheză 12-01-2024
Raport public de evaluare Raport public de evaluare portugheză 07-05-2014
Prospect Prospect română 12-01-2024
Caracteristicilor produsului Caracteristicilor produsului română 12-01-2024
Raport public de evaluare Raport public de evaluare română 07-05-2014
Prospect Prospect slovacă 12-01-2024
Caracteristicilor produsului Caracteristicilor produsului slovacă 12-01-2024
Raport public de evaluare Raport public de evaluare slovacă 07-05-2014
Prospect Prospect slovenă 12-01-2024
Caracteristicilor produsului Caracteristicilor produsului slovenă 12-01-2024
Raport public de evaluare Raport public de evaluare slovenă 07-05-2014
Prospect Prospect finlandeză 12-01-2024
Caracteristicilor produsului Caracteristicilor produsului finlandeză 12-01-2024
Raport public de evaluare Raport public de evaluare finlandeză 07-05-2014
Prospect Prospect suedeză 12-01-2024
Caracteristicilor produsului Caracteristicilor produsului suedeză 12-01-2024
Raport public de evaluare Raport public de evaluare suedeză 07-05-2014
Prospect Prospect norvegiană 12-01-2024
Caracteristicilor produsului Caracteristicilor produsului norvegiană 12-01-2024
Prospect Prospect islandeză 12-01-2024
Caracteristicilor produsului Caracteristicilor produsului islandeză 12-01-2024
Prospect Prospect croată 12-01-2024
Caracteristicilor produsului Caracteristicilor produsului croată 12-01-2024
Raport public de evaluare Raport public de evaluare croată 07-05-2014

Căutați alerte legate de acest produs

Vizualizați istoricul documentelor